Docefrez and Breastfeeding

Because no research has been done on breastfeeding and Docefrez, it is unknown if the drug passes through human breast milk or if it would cause problems in a nursing infant. However, the medicine is known to pass through breast milk in animals. Due to the risk of potentially serious complications, the manufacturer recommends that women avoid breastfeeding while undergoing treatment.

Can Breastfeeding Women Receive Docefrez?

Docefrez™ (docetaxel) is a prescription chemotherapy medication used to treat certain people with breast, prostate, or lung cancer. At this time, it is unknown whether Docefrez passes through breast milk in humans. The manufacturer of the drug recommends that women not breastfeed during Docefrez treatment.
 

More Information on Docefrez and Breastfeeding

Docefrez has not been studied in women who are breastfeeding. Therefore, it is unknown if the drug passes through breast milk or if it would harm a nursing infant.
 
Docetaxel, the active ingredient in Docefrez, has been shown to pass through breast milk in animals. Because Docefrez is associated with dangerous side effects, it is generally recommended that women stop breastfeeding while using the medication.
 

Talking With Your Healthcare Provider

You should discuss breastfeeding and Docefrez use with your healthcare provider. Each woman's situation is different, and you and your healthcare provider understand your situation best. After considering what you want and expect, as well as your current health situation, the two of you can make a shared decision that is right for you.
Baby Milestones You've Never Heard Of

Docefrez Chemotherapy Information

Referring Pages:
Terms of Use
Advertise with Us
Contact Us
About eMedTV
Privacy Policy
Copyright © 2006-2017 Clinaero, Inc.
eMedTV serves only as an informational resource. This site does not dispense medical advice or advice of any kind. Site users seeking medical advice about their specific situation should consult with their own physician. Click Terms of Use for more information.